Argentarii LLC Reduces Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Argentarii LLC decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,808 shares of the medical research company’s stock after selling 67 shares during the period. Argentarii LLC’s holdings in Thermo Fisher Scientific were worth $900,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of TMO. Sierra Ocean LLC grew its holdings in shares of Thermo Fisher Scientific by 54.5% during the first quarter. Sierra Ocean LLC now owns 119 shares of the medical research company’s stock worth $59,000 after purchasing an additional 42 shares during the last quarter. Vickerman Investment Advisors Inc. acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $393,000. Adell Harriman & Carpenter Inc. increased its holdings in shares of Thermo Fisher Scientific by 8.6% in the 1st quarter. Adell Harriman & Carpenter Inc. now owns 12,824 shares of the medical research company’s stock valued at $6,381,000 after acquiring an additional 1,012 shares during the period. Concurrent Investment Advisors LLC boosted its stake in Thermo Fisher Scientific by 11.1% during the 1st quarter. Concurrent Investment Advisors LLC now owns 3,822 shares of the medical research company’s stock worth $1,902,000 after purchasing an additional 382 shares during the period. Finally, Simmons Bank increased its stake in Thermo Fisher Scientific by 1.0% in the first quarter. Simmons Bank now owns 8,389 shares of the medical research company’s stock valued at $4,174,000 after purchasing an additional 86 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TMO. Barclays lowered their price target on Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a report on Tuesday, June 24th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Evercore ISI cut their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Finally, Scotiabank cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research report on Friday, April 25th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $604.05.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares of the company’s stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO opened at $428.25 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The stock has a market cap of $161.66 billion, a P/E ratio of 25.12, a P/E/G ratio of 2.28 and a beta of 0.77. The stock’s 50 day simple moving average is $409.18 and its 200 day simple moving average is $479.65. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the business posted $5.11 earnings per share. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.